City

Baltimore (1)

Basel (1)

Bethesda (1)

Ithaca (1)

New York (1)

Palo Alto (1)

Philadelphia (1)

Salt Lake City (1)

Washington (1)

Condition

Essential Thrombocythemia (1)

Myelodysplastic Syndromes (1)

Myelofibrosis (1)

Polycythemia Vera (1)

Severe Aplastic Anemia (1)

Overall Status

Completed (1)

Recruiting (1)

Unknown status (1)

Phase

phase 1/phase 2 (2)

phase 3 (1)

Sponsor

National Heart, Lung, and Blood Institute (NHLBI) (1)

Ronald Hoffman (1)

Swiss Group for Clinical Cancer Research (1)

Collaborator

Myeloproliferative Disorders-Research Consortium (1)

National Cancer Institute (NCI) (1)

Novartis (1)

Intervention

atg + csa (1)

cep-701 (lestaurtinib) (1)

cohort 1: hatg, csa, epag day 14 to month 6 (1)

cohort 2: hatg, csa, epag day 14 to month 3 (1)

cohort 3: hatg, csa (dose reduced), epag day 1 to month 6 (1)

extension cohort (1)

supportive care (1)

Study Documents

Intervention Type

drug (3)

behavioral (1)

Funder Type

Other (2)

NIH (1)

Study Type

Interventional (3)

Hematopoesis

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Severe Aplastic Anemia Trial run by the NHLBI (Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to

Recruiting

Has Results

Severe Aplastic Anemia

Cohort 1: hATG, CsA, EPAG Day 14 to Month 6
+3 more

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Apr 5, 2022

MDS Trial in Basel (ATG + CSA, Supportive care)

Completed

Myelodysplastic Syndromes

ATG + CSA
Supportive care

Basel, Switzerland

Universitaetsspital-Basel

Mar 10, 2015

Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera Trial in United States (CEP-701 (Lestaurtinib))

Unknown status

Myelofibrosis
+2 more

CEP-701 (Lestaurtinib)

Palo Alto, California
+6 more

Nov 24, 2014